TMCITMCIHealthcare · Medical Devices

TMCI Stock Forecast: Treace Medical Concepts, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$4.31
−0.92% on the day

The 5 Wall Street analysts covering Treace Medical Concepts, Inc. hold a median 12-month price target of $6.5 — +50.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 55 of 100 as at 21 Nov 2026 — in the upper half.

Market cap
$282.6M
Ticker Nerd rank
55/ 100
Median analyst target
$6.50
Analysts covering
5
Revenue$45.4M−4.2% y/y
Operating income−$15.0M
Net income−$15.9M
Free cash flow−$6.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−18.2%
1M
+5.9%
YTD
+75.9%
1Y
+65.1%
From 52W high
−19.3%
From 52W low
+259.2%
$1.20
$5.34
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Treace Medical Concepts, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
55/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
85
Revisions
77
Quality
58
Value
47
Momentum
43
Issuance
31
Growth
30
Volatility
16

Accruals (85): Reported profit is backed by cash, and the company is not expanding recklessly.

Volatility (16): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

TMCI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TMCI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$2.00$3.00$4.00$5.00$6.00$7.00Jan 26Apr 26Jul 26Oct 26TMCIHigh $7.00Median $6.50Low $5.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
2
Buy
2
Hold
1
Sell
$5.00
Low
$6.50
Median
$7.00
High

The green dot is the last close — the median target sits +50.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
9 Nov 2026StifelUpgradeBuy$4.50 → $6.50
10 Aug 2026Truist SecuritiesMaintainsHold$4.00 → $5.00
16 July 2026Truist SecuritiesMaintainsHold$2.00 → $4.00
2 Mar 2026Lake StreetMaintainsBuy—
7 Jan 2026StifelMaintainsHold—
18 Dec 2025Truist SecuritiesMaintainsHold—
10 Nov 2025Truist SecuritiesReiteratesHold—
7 Nov 2025BTIGDowngradeNeutral—
7 Nov 2025JP MorganDowngradeUnderweight—
7 Nov 2025UBSMaintainsNeutral—
15 Oct 2025Truist SecuritiesMaintainsHold—
4 Sept 2025Truist SecuritiesMaintainsHold—
8 Aug 2025StifelMaintainsHold—
8 Aug 2025UBSMaintainsNeutral—
9 May 2025UBSMaintainsNeutral—
11 Apr 2025Truist SecuritiesMaintainsHold—
13 Mar 2025Truist SecuritiesMaintainsHold—
3 Mar 2025Truist SecuritiesMaintainsHold—
31 Dec 2024Lake StreetInitiatesBuy—
18 Dec 2024Truist SecuritiesMaintainsHold—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for TMCI.

Market Radar

This page is one stock. Monday covers all of them.

TMCI appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

TMCI vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Treace Medical Concepts, Inc. returned +65.1% against +6.9% for the S&P 500, dividends included.

TMCI vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200Jan 26Apr 26Jul 26Oct 26TMCIS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TMCI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
1.4×

Cheaper than 58% of US stocks

Price / book
4.6×

Cheaper than 20% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
−3.9%

Higher than 22% of US stocks

Earnings growth (YoY)
—
Gross margin
78.5%

Higher than 90% of US stocks

Operating margin
−24.4%

Higher than 22% of US stocks

Net margin
−27.4%

Higher than 14% of US stocks

Returns & dividend
Return on equity
−74.0%

Higher than 17% of US stocks

Return on assets
−16.5%

Higher than 22% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Treace Medical Concepts, Inc. has a market value of $282.6M and an enterprise value of $317.6M.

  • Revenue in the twelve months to 30 June 2026: $205.3M. The latest quarter shrank 4.2% year on year.

  • Net income over the same four quarters: −$59.5M, a −29.0% net margin.

  • Diluted earnings per share, trailing twelve months: −$0.93.

  • Free cash flow in the twelve months to 30 June 2026: −$25.0M.

  • Shares outstanding: 65.0M.

  • Treace Medical Concepts, Inc. employs 450 people — $456K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

TMCI and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
TMCITreace Medical Concepts, Inc.$282.6M55
NPCENeuroPace, Inc.$267.7M73
INFUInfuSystem Holdings, Inc.$285.8M100
LABStandard BioTools, Inc.$246.1M41
SSIISS Innovations International, Inc.$245.9M11
OFIXOrthofix Medical, Inc.$240.4M60
VMDViemed Healthcare, Inc.$323.9M99

Take a look at TMCI’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Treace Medical Concepts, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about TMCI

What is the TMCI stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Treace Medical Concepts, Inc. have a median 12-month price target of $6.5, with estimates ranging from $5 to $7. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TMCI stock a buy right now?

Of the 5 analysts covering Treace Medical Concepts, Inc., 2 rate it a Buy, 2 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Treace Medical Concepts, Inc. 55 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TMCI?

As at 21 Nov 2026, Treace Medical Concepts, Inc. ranks 55 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (85 of 100).

Will TMCI stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +50.8% from the last close, and Ticker Nerd's factor model ranks Treace Medical Concepts, Inc. 55 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TMCI stock forecast for 2030?

No analyst covering Treace Medical Concepts, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TMCI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $7 over the next 12 months.

How has TMCI stock performed over the past year?

Treace Medical Concepts, Inc. returned +65.1% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Treace Medical Concepts, Inc. do?

Treace Medical Concepts Inc. is a medical technology company focused on orthopedic solutions for foot and ankle care. Its core offerings include surgical systems, instruments, implants, and biologic solutions designed for the treatment of bunion deformities and related midfoot conditions.

Company

About Treace Medical Concepts, Inc.

Treace Medical Concepts Inc. is a medical technology company focused on orthopedic solutions for foot and ankle care. Its core offerings include surgical systems, instruments, implants, and biologic solutions designed for the treatment of bunion deformities and related midfoot conditions. The company’s product portfolio is centered on procedures that help surgeons address the underlying structure of hallux valgus, with systems such as Lapiplasty supporting three-dimensional bunion correction. Treace Medical Concepts serves orthopedic surgeons, podiatrists, ambulatory surgery centers, and other healthcare providers involved in foot and ankle surgery. Its products are used in commercial-stage clinical settings and are part of the broader medical devices market, where the company contributes specialized tools intended to improve procedural consistency and surgical workflow. Headquartered in Ponte Vedra Beach, Florida, Treace Medical Concepts operates as a focused player in the musculoskeletal device segment, with an emphasis on dedicated treatment solutions for bunion and midfoot procedures.

CEO Mr. John T. Treace · 450 employees · United States · https://www.treace.com